GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Translate Bio Inc (NAS:TBIO) » Definitions » Beneish M-Score

Translate Bio (Translate Bio) Beneish M-Score : 3.05 (As of Apr. 26, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Translate Bio Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 3.05 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Translate Bio's Beneish M-Score or its related term are showing as below:

TBIO' s Beneish M-Score Range Over the Past 10 Years
Min: -0.29   Med: 5.95   Max: 14.94
Current: 3.05

During the past 5 years, the highest Beneish M-Score of Translate Bio was 14.94. The lowest was -0.29. And the median was 5.95.


Translate Bio Beneish M-Score Historical Data

The historical data trend for Translate Bio's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Translate Bio Beneish M-Score Chart

Translate Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20
Beneish M-Score
- - - 0.67 11.19

Translate Bio Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.13 10.90 11.19 8.85 3.05

Competitive Comparison of Translate Bio's Beneish M-Score

For the Biotechnology subindustry, Translate Bio's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Translate Bio's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Translate Bio's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Translate Bio's Beneish M-Score falls into.



Translate Bio Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Translate Bio for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.1844+0.528 * 1+0.404 * 0.4518+0.892 * 8.6144+0.115 * 2.3746
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.1633+4.679 * -0.28633-0.327 * 1.0092
=2.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun21) TTM:Last Year (Jun20) TTM:
Total Receivables was $24.0 Mil.
Revenue was 72.649 + 34.6 + 51.391 + 66.446 = $225.1 Mil.
Gross Profit was 72.649 + 34.6 + 51.391 + 66.446 = $225.1 Mil.
Total Current Assets was $717.0 Mil.
Total Assets was $904.9 Mil.
Property, Plant and Equipment(Net PPE) was $86.4 Mil.
Depreciation, Depletion and Amortization(DDA) was $10.1 Mil.
Selling, General, & Admin. Expense(SGA) was $42.6 Mil.
Total Current Liabilities was $81.5 Mil.
Long-Term Debt & Capital Lease Obligation was $46.2 Mil.
Net Income was 17.144 + 26.522 + -20.561 + 17.344 = $40.4 Mil.
Non Operating Income was -4.088 + 44.133 + -28.409 + -13.595 = $-2.0 Mil.
Cash Flow from Operations was 13.005 + 0.689 + -21.976 + 309.781 = $301.5 Mil.
Total Receivables was $15.1 Mil.
Revenue was 16.319 + 4.654 + 3.89 + 1.266 = $26.1 Mil.
Gross Profit was 16.319 + 4.654 + 3.89 + 1.266 = $26.1 Mil.
Total Current Assets was $316.2 Mil.
Total Assets was $454.3 Mil.
Property, Plant and Equipment(Net PPE) was $25.3 Mil.
Depreciation, Depletion and Amortization(DDA) was $8.4 Mil.
Selling, General, & Admin. Expense(SGA) was $30.3 Mil.
Total Current Liabilities was $51.8 Mil.
Long-Term Debt & Capital Lease Obligation was $11.8 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(24.03 / 225.086) / (15.131 / 26.129)
=0.106759 / 0.579088
=0.1844

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(26.129 / 26.129) / (225.086 / 225.086)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (717.012 + 86.372) / 904.87) / (1 - (316.221 + 25.284) / 454.278)
=0.112155 / 0.248247
=0.4518

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=225.086 / 26.129
=8.6144

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(8.389 / (8.389 + 25.284)) / (10.124 / (10.124 + 86.372))
=0.249131 / 0.104916
=2.3746

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(42.6 / 225.086) / (30.288 / 26.129)
=0.189261 / 1.159172
=0.1633

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((46.171 + 81.514) / 904.87) / ((11.751 + 51.766) / 454.278)
=0.141109 / 0.13982
=1.0092

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(40.449 - -1.959 - 301.499) / 904.87
=-0.28633

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Translate Bio has a M-score of 2.30 signals that the company is likely to be a manipulator.


Translate Bio Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Translate Bio's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Translate Bio (Translate Bio) Business Description

Traded in Other Exchanges
N/A
Address
29 Hartwell Avenue, Lexington, MA, USA, 02421
Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, for the treatment of cystic fibrosis (CF) and MRT5201, for the treatment of ornithine transcarbamylase (OTC) deficiency.
Executives
Jean Francois Formela director C/O ATLAS VENTURE, 890 WINTER STREET, WALTHAM MA 02451
Renaud Ronald C Jr director, officer: Chief Executive Officer, other: President C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02109
Paul D. Burgess officer: Chief Operating Officer, CLO, other: Secretary C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Owen Hughes director C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Shire Human Genetic Therapies, Inc. 10 percent owner 300 SHIRE WAY LEXINGTON MA 02421
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
Baupost Group Gp, L.l.c. 10 percent owner 10 ST. JAMES AVENUE, SUITE 1700, BOSTON MA 02116
Seth A Klarman 10 percent owner 10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Baupost Group Llc/ma 10 percent owner 10 ST JAMES AVE, SUITE 1700, BOSTON MA 02116
George Demetri director BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Daniella Beckman director C/O IDENIX PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG. 1400, CAMBRIDGE MA 02139
Robert M Plenge director C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Daniel Lynch director
Robert J. Meyer director 2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713
Ann Barbier officer: Chief Medical Officer 255 STATE STREET, C/O PIERIS PHARMACEUTICALS,INC., BOSTON MA 02109